A pair of deals in the fourth quarter of 2024 highlights the attraction of the patient-direct market for continuous glucose ...

With the latest acquisition of Acentus, Henry Schein’s homecare medical products platform will now have an annual revenue base of approximately $350 million. Accordingly, we expect market sentiment to ...

Merck , known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m.

Mikart, a leading Contract Development and Manufacturing Organization (CDMO) specializing in small-molecule pharmaceutical ...

Provident Healthcare Partners ("Provident"), a leading healthcare investment banking firm, announced it has advised Acentus ...

Evercore ISI analyst Elizabeth Anderson CFA maintained a Hold rating on Henry Schein (HSIC – Research Report) yesterday and set a price target ...

Tampa, Florida-based Acentus, a national medical supplier, specializes in the delivery of continuous glucose monitors (CGMs).

The Acentus transaction follows Henry Schein’s acquisition of Prism Medical Products, LLC in 2021 and Shield Healthcare and ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

NAW said Henry Schein’s CEO won the award for his leadership, service and engagement with the association and distribution ...